Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aureon Biosciences
Yonkers, New York, United States
- Ownership
- Private
- Employees
- ~260
- Development stage
- Other
01
Overview
Aureon Biosciences commercialized predictive molecular pathology tests for cancer, primarily prostate cancer (Prostate Px), using advanced image and tissue analysis to enable personalized therapy decisions; the approach integrated clinical, molecular, and anatomical features for improved prognostic accuracy. The company collaborated with major cancer centers and pharmaceutical partners but is no longer active.
- Therapeutic areas
- Oncology
- Modalities
- Diagnostic testMolecular diagnosticsProtein biomarker analysisTissue-based image analysis
- Industry
- Molecular Diagnostics
02
Partnerships
Major cancer centersbio-pharmaceutical partners for drug discovery and clinical development
Beyond the preview
Go deeper on Aureon Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aureon Biosciences.